Efficacy and safety of interleukin‐17 antagonists in patients with plaque psoriasis: a meta‐analysis from phase 3 randomized controlled trials. (8th February 2017)

• Record Type: Journal Article
• Authors: Wu, D.; Hou, S.‐Y.; Zhao, S.; Hou, L.‐X.; Jiao, T.; Xu, N.‐N.; Zhang, N.
• Is Part Of: Journal of the European Academy of Dermatology and Venereology. Volume 31:Number 6(2017)
• Page Start: 992
• Page End: 1003
• Publication Date: 2017-02-08
• Subjects: Dermatology -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1111/jdv.14125
• Languages: English
• ISSNs: 0926-9959

Abstract

Abstract: Background: The interleukin‐17 (IL‐17) cytokine pathway plays a key role in the development of psoriasis. Antibodies targeting IL‐17 or blocking its receptor may be a new therapeutic approach for psoriasis. To assist treatment selection in daily practice, it is essential to understand the benefit and risk profile of IL‐17 antagonists. Objective: We performed a meta‐analysis to evaluate the efficacy and safety of IL‐17 antagonists in patients with psoriasis. Methods: We searched a number of databases for relevant randomized controlled trials (RCTs) published before May 2016. The following outcomes were evaluated: Psoriasis Area and Severity Index (PASI) 75, 90, 100 response, Investigator's Global Assessment (IGA) score of 0 or 1 response, adverse events (AEs) and withdrawals. The meta‐analysis was performed using Review Manager 5.2 software. Results: Nine RCTs with 5951 patients were included. IL‐17 antagonists achieved higher PASI 75, 90, 100 response rates and Dermatology Life Quality Index 0 or 1 response rates than placebo and a lower incidence of discontinuations due to lack of efficacy. In the safety analysis, no significant differences were found between the IL‐17 antagonists and placebo in the proportion of patients with serious AEs, cardiovascular disease and discontinuations due to AEs. However, IL‐17 antagonists were associated with a higher proportion of patients with any AEs and infections than placebo. Conclusion: IL‐17 antagonists were effective, with an acceptable safety profile, for patients with plaque psoriasis. Vigilance because of the potential for infection will be necessary for IL‐17 antagonists.